Abstract Details

Title Multiple Sclerosis Characteristics Do Vary According to Age of Disease Onset

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 118

Objective

To compare demographic data, clinical features and disease progression of individuals with early onset (Eo) and adult onset (Ao) Multiple Sclerosis (MS).

Background

Age at MS onset is considered as an indicator of the disease course in different studies. However, some authors suggested no impact of age of onset on the prognosis.

Design/Methods This retrospective study was conducted in the department of neurology of Razi hospital and included patients diagnosed with MS according to the McDonald’s diagnostic criteria. Patients were divided into two groups: EoMS (age≤18 years) and AoMS (18<age at MS<50 years). Demographic data, clinical symptoms and disability progression (progression index (PI), Multiple sclerosis severity score (MSSS) and Expanded disability status scale (EDSS)) were compared between the two groups. P value<0.05 was considered as statistically significant.

Results We included 477 patients: 57 EoMS (11.9% -mean age of onset= 15.7±2,2 years) and 420 AoMS (88.1% - mean age of onset=30±7.8 years). Female predominance was more important during EoMS (sex-ratio=3.38 versus 2.33 for AoMS; p=0.2). During first relapse, bladder and bowel dysfunction was less common during EoMS (1.75%) compared with AoMS (9,7%; p=0.045). MS was relapsing in 92.9% of EoMS and 76.6% of AoMS, secondary progressive in 5.2% of AoMS and 15.7% of AoMS and primary progressive in 1.7% of EoMS and 7.6% of AoMS (p=0.018). During EoMS, median PI (0,21 versus 0,3 ; p=0.03) and MSSS (2.74 versus 3,67 ; p=0.032) were lower compared with AoMS. Mean EDSS scores during the third and fifth years (1.08 for EoMS versus 1.8 for AoMS ; p=0,1) (1.7 for EoMS versus 1.4 for AoMS ; p=0,2) were also lower for EoMS.

Conclusions

Patients with EoMS had more relapsing forms, more active disease and lower disability progression compared to AoMS.

Authors/Disclosures
Saloua Mrabet, MD (Razi University Hospital) PRESENTER	Dr. Mrabet has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Imen Kacem, MD (Department of Neurology)	Dr. Kacem has nothing to disclose.
Saloua Mrabet, MD (Razi University Hospital)	Dr. Mrabet has nothing to disclose.

��ɫ��

��ɫ��